



OSMOSENSING, OSMOSIGNALLING AND INFLAMMATION: HOW INTERVERTEBRAL DISC CELLS RESPOND TO ALTERED OSMOLARITY

A. Sadowska^{1,§}, T. Kameda^{1,2,§}, O. Krupkova¹ and K. Wuertz-Kozak^{1,3,4,5,*}

¹Institute for Biomechanics, D-HEST, ETH Zurich, Zurich, Switzerland ²Department of Orthopaedic Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan ³Spine Centre, Schön Clinic Munich Harlaching, Munich, Germany ⁴Department of Health Sciences, University of Potsdam, Potsdam, Germany ⁵Academic Teaching Hospital and Spine Research Institute, Paracelsus Private Medical University Salzburg, Salzburg, Austria

[§]These authors contributed equally

Abstract

Intervertebral disc (IVD) cells are naturally exposed to high osmolarity and complex mechanical loading, which drive microenvironmental osmotic changes. Age- and degeneration-induced degradation of the IVD's extracellular matrix causes osmotic imbalance, which, together with an altered function of cellular receptors and signalling pathways, instigates local osmotic stress. Cellular responses to osmotic stress include osmoadaptation and activation of pro-inflammatory pathways. This review summarises the current knowledge on how IVD cells sense local osmotic changes and translate these signals into physiological or pathophysiological responses, with a focus on inflammation. Furthermore, it discusses the expression and function of putative membrane osmosensors (*e.g.* solute carrier transporters, transient receptor potential channels, aquaporins and acid-sensing ion channels) and osmosignalling mediators [*e.g.* tonicity response-element-binding protein/nuclear factor of activated T-cells 5 (TonEBP/NFAT5), nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B)] in healthy and degenerated IVDs. Finally, an overview of the potential therapeutic targets for modifying osmosensing and osmosignalling in degenerated IVDs is provided.

Keywords: Intervertebral disc degeneration, degenerative disc disease, osmolarity, hyper-osmolarity, hypoosmolarity, osmotic, inflammatory, transient receptor potential channel, aquaporin, tonicity-responsive enhancer binding protein.

*Address for correspondence: Karin Wuertz-Kozak, Institute for Biomechanics, D-HEST, ETH Zurich, Hönggerbergring 64, HPP-O12, 8093 Zurich, Switzerland. Telephone number: +41 446338126 Email: kwuertz@ethz.ch

Copyright policy: This article is distributed in accordance with Creative Commons Attribution Licence (http://creativecommons.org/licenses/by-sa/4.0/).

List of abbreviations		CRISPR	clustered regularly interspaced short palindromic repeats
4α PDD	4α -phorbol-12,13-didecanoate	CS	chondroitin sulphate
ADAMTS	a disintegrin and metalloproteinase	dCas	deactivated Cas
	with thrombospondin motifs	DDD	degenerative disc disease
AF	annulus fibrosus	ECM	extracellular matrix
AQPs	aquaporins	ERK	extracellular signal-regulated kinase
ASICs	acid sensing ion channels	GAG	glycosaminoglycan
ATM	ataxia telangiectasia-mutated	IL	interleukin
BMP-2	bone morphogenetic protein 2	IVD	intervertebral disc
Cas	CRISPR-associated	JNK	c-Jun NH ₂ -terminal kinase
CNS	central nervous system	KRAB	Krüppel-associated box

KS	keratan sulphate
MAPKs	mitogen-activated protein kinases
MMPs	matrix metalloproteinases
NF-ĸB	nuclear factor kappa-light-chain-
	enhancer of activated B cells
NLRP3	NOD-like receptor protein 3
NOD	nucleotide-binding domain
NP	nucleus pulposus
OREBP	osmotic response-element-binding
	protein
PGE2	prostaglandin E2
PGs	proteoglycans
PKC	protein kinase C
ROS	reactive oxygen species
RVD	regulatory volume decrease
RVI	regulatory volume increase
SLC	solute carrier
TFG-β	transforming growth factor- β
TNF-α	tumour necrosis factor- α
TonEBP/NFAT5	tonicity response element-binding
	protein/nuclear factor of activated
	T-cells 5
TRP	transient receptor potential
TRPV	TRP vanilloid
TZ	transition zone

Introduction

The IVD is a mechanically loaded tissue with early signs of degeneration that are associated with a loss of PGs and, thus, changes in the osmotic environment (Roughley et al., 2002; Urban and McMullin, 1988). The IVD contains a small population of cells embedded in an ECM that is predominantly composed of water (60-99 %) (Cassinelli et al., 2001; Oegema, 1993). The mechanical properties of the IVD are determined by its biochemical structure, with the highly hydrated NP in the middle, surrounded by the AF. The AF is rich in collagen type I towards the outer rim, where it provides greater strength, whereas the inner part is composed of fibrocartilage that steadily fuses into a TZ with the NP (Urban and Roberts, 2003). The NP, an immune-privileged structure, consists of sparsely distributed cells surrounded by a gelatinous network that is primarily composed of collagen type II and PGs (Takada et al., 2002), showing the IVD's similarity to cartilage. With aging, the IVD undergoes degenerative changes, which are associated with tissue weakening, dehydration and loss of ECM components (Luoma et al., 2000; Maher et al., 2017). Associated changes in tissue hydration and, hence, in the IVD's osmotic environment influence the IVD's mechanical properties (Wuertz et al., 2007), possibly leading to lower-back pain, activity limitation, disability (Walker, 2000) and, consequently, a high economic burden on the society (Wieser et al., 2011). The goals of this review were (1) to summarise the current knowledge on how IVD cells sense and respond to osmotic changes, (2) to provide an outlook on possible future research on disc hydration and osmolarity and (3) to highlight potential therapies related to IVD osmosignalling.

Osmoregulation

General concept of osmoregulation

The capacity to maintain an osmotic balance (= osmoregulation) and control the cell volume is important for preserving cell function. The volume of a cell depends on the water movements across its membrane, driven by osmotic gradients that develop from differences in the chemical concentrations of the intra- and extra-cellular fluids under normal physiological conditions (Lodish et al., 2000). Solutions with higher solvent concentration tend to have a lower water content and vice versa. Hence, water will move across the membrane from the solution with the lower solute (or higher water) content to the one with the higher solute (or lower water) content - a phenomenon that is defined as osmosis (Lodish et al., 2000). Osmolarity (or osmotic concentration) is the concentration of solutes in a solution and it is expressed in osmol/L, whereas osmolality is expressed in osmol/kg (or Osm/kg); both terms are often used interchangeably (Baltz, 2012). A decrease or increase in the extracellular osmolarity will result in cell swelling (= inflow of water) or cell shrinkage (= outflow of water), respectively (Hoffmann et al., 2009). To resist cell swelling, the osmotic pressure - defined as a minimal hydrostatic pressure necessary to stop water from diffusing across two barriers - has to be developed (Lodish et al., 2000).

Osmoregulation in the IVD

PGs are crucial for maintaining hydration and osmotic pressure in the IVD, with aggrecan being the primary type (Urban and Roberts, 2003). Aggrecans are composed of three globular domains (G1, G2, G3) and attached GAG side chains (Sivan et al., 2014). The primary types of GAGs found in the IVD are CS and KS. The ionic balance of the IVDs extracellular matrix is regulated by the negatively charged GAGs (Johnson et al., 2014). The sulphated GAGs of the aggrecans create a high negative charge, contributing to the aggrecan's ability to electrostatically bind water. On the tissue level, this translates into the generation of an osmotic pressure in the IVD, causing the NP to ingest water; it also contributes to the high swelling pressure and load-bearing ability of the IVD (Erwin and Hood, 2014; Urban and Maroudas, 1981; Urban et al., 1979; Urban and Roberts, 2003) and the resistance to high compressive loads experienced, for example, during weight lifting or forward bending activities (Shirazi-Adl, 2006). If the applied loading exceeds the osmotic pressure, water is diffused and the osmotic pressure increases, while water is absorbed during IVD unloading, resulting in an osmotic equilibrium (McMillan et al., 1996; Urban, 1993). In the lack of external loads, the hydrostatic



pressure is maintained due to the structure of the AF and endplates that constrain the swelling of the NP (Newell *et al.*, 2017). *In vivo* studies demonstrate that the NP's water content decreases by around 15 % under loading conditions (human lumbar IVDs, unloaded *vs.* loaded, 1500 N, 6 h) (McMillan *et al.*, 1996). However, in contrast to static or high-impact loading, daily physiological loading, such as dynamic loading or loading at moderate speed [*e.g.* jogging (Belavy *et al.*, 2017)], are beneficial for the IVD's hydration and, therefore, the tissue's health (Belavy *et al.*, 2016).

For a normal osmotic function in the IVD, it is essential that the aggrecan content, charge and size remain as large as possible. However, aggrecans are enzymatically cleaved by proteinases such as MMPs and aggrecanases, whose expression increases in degenerated IVDs (Le Maitre et al., 2004; Molinos et al., 2015; Sztrolovics et al., 1997). Age-related or degeneration-induced loss of aggrecan causes a drop in osmotic pressure, reducing the IVD's ability to respond to mechanical loads. In a healthy state, the extracellular osmolarity can vary from ~ 430 (iso-osmotic) to ~ 496 mOsm/L (hyper-osmotic) (Ishihara et al., 1997; van Dijk et al., 2011) – values which are in a physiological range for IVD cells but would be considered high for most mammalian cells (Appelboom et al., 1956; Brocker et al., 2012). The IVD's osmolarity can decrease to around 300 mOsm/L (hypo-osmotic) in degenerated IVDs (Wuertz et al., 2007) due to a loss of PGs and, thus, IVD hydration and occurrence of fibrosis; however, the same osmolarity would be considered physiological for cells of other tissues (Hooper et al., 2015). In this review, the terms: hyper-, hypo- and iso-osmotic are used in the context of the IVD tissue. Although an altered osmotic environment is rather a hallmark of IVD degeneration than its primary cause, the reduced tissue osmolarity can activate and/or interplay with pro-inflammatory factors and catabolic responses and, hence, promote IVD inflammation and DDD (see 'Cell responses to osmotic changes: target genes and signalling pathways').

Osmolarity-related cell volume changes

At the cellular level, a change in intra- or extracellular osmolarity causes mammalian cell volume regulation by the solubility-diffusion water transport across the cell membrane through several water, ion and molecule transport pathways, such as pores, ion channels and membrane carriers (see 'Membrane proteins as potential osmosensors in the IVD') (Dawson, 1988; Reuss, 2012). The increased cell volume induces a prompt activation of the RVD, a mechanism that acts to recover the cell volume homeostasis. In contrast, hyper-osmolarity causes cell shrinkage, to which a cell responds by activating the RVI mechanism (McManus et al., 1995). However, very limited information on the cell volume regulation in the IVD exists. In bovine NP cells, a decrease in extra-cellular osmolarity (from 430 to 230 mOsm/L) increases the cell volume by up to 20 %, leading to a reduced PG synthesis rate (Ishihara et al., 1997). Changes in the IVD cell volume may involve depolarisation and reorganisation of the actin cytoskeleton and initiation of calcium transits from the intra-cellular stores (Pritchard et al., 2002). Interestingly, the response to the hyperosmotically-induced volume changes may be zonedependent (AF vs. NP) due to the differences in the mechanical composition of these cells. In comparison with AF cells, NP cells were found to be stiffer and more viscous due to differences in the cytoskeletal arrangement (Guilak et al., 1999). Additionally, vacuoles (or vesicles), which can be found in the notochordal cells within the NP tissue (canine), contain a low-osmolarity solution that is released into the cytoplasm under a condition of hyper-osmotic stress and helps to restore the osmotic balance (Hunter et al., 2007). However, this mechanism has not been confirmed in other notochordal-free species and, therefore, cannot be generalised.

Membrane proteins as potential osmosensors in the IVD

Cells sense osmotic stress through membrane proteins such as carriers (SLC) or channels (TRP and AQPs) (Table 1**a-c**, Table 2, Fig. 1), which are responsible for transporting molecules (*e.g.* ions, sugars *etc.*) across the cell membrane. Carriers physically bind to a specific solute and change their own conformation to release the solute on the other side of the cell membrane; channels form a pore, which can open to allow a specific molecule to pass by diffusion or osmosis (Kulbacka *et al.*, 2017).

The SLC is a group of membrane transport proteins that includes over 400 transporters in humans. The SLC transporters play an important role in homeostasis by transporting soluble molecules (such as nutrients) across the lipid membranes (Perland and Fredriksson, 2017) and are involved in i.e. glucose transport (SLC5) (Hediger et al., 2004), pH regulation (SLC16) (Jones and Morris, 2016), hormone and/or drug uptake (SLC21A12) (Alam et al., 2016; Williams, 2013; Zair et al., 2008). As shown in human NP cells, an increase in osmolarity (450 mOsm/L) upregulates the expression of the solute carriers SLC21A12 (= SLCO) and SLC5A3 but downregulates the expression of SLC16A6 (Boyd et al., 2005). Although they have a putative role in regulatory volume mechanisms in other tissue types (Arroyo et al., 2013), their exact role in the IVD is largely unknown.

The TRP channels, a superfamily of cation-selective transmembrane receptors, have recently emerged as potential contributors to IVD degeneration and discogenic pain (Alfredo Franco-Obregón, 2017; Krupkova *et al.*, 2017; Sadowska *et al.*, 2017; Walter *et al.*, 2016). TRP channels are multimodal ion channels regulated by a diverse range of stimuli, including mechanical and osmotic stress (Krupkova *et al.*, 2017; Numata *et al.*, 2011). Previous studies examining



Table 1a. Targets regulated by hyper-osmotic treatment. \uparrow = upregulation, \downarrow = downregulation. Only selected targets are discussed in the text.

Target gene (symbol)	Expression level change	Function	Model	Reference
Guanylate binding protein 1 (GBP1)	Gene↓	Cell-cell interaction/ adhesion	Human IVD tissue	Boyd <i>et al.,</i> 2005
Kelch motif protein (KIAA1309)	Gene↓	Cell-cell interaction/ adhesion	Human IVD tissue	Boyd <i>et al.,</i> 2005
Small inducible cytokine A2 (SCYA2)	Gene↓	Cell-cell interaction/ adhesion	Human IVD tissue	Boyd <i>et al.,</i> 2005
Vascular cell adhesion molecule 1 (VCAM1)	Gene↓	Cell-cell interaction/ adhesion	Human IVD tissue	Boyd <i>et al.,</i> 2005
Cyclin-dependent kinase inhibitor 1 (p21 ^{WAF1})	Protein ↑	Cell-cycle, arrest of G0/ G1	Bovine NP cells	Mavrogonatou and Kletsas, 2009
Phospho- p38 MAPK	Protein ↑	Cell-cycle, arrest of G0/ G1	Bovine NP cells	Mavrogonatou and Kletsas, 2009
Phospho- p53 MAPK	Protein ↑	Cell-cycle, arrest of G0/ G1	Bovine NP cells	Mavrogonatou and Kletsas, 2009
Aryl hydrocarbon receptor translocator-like (ARNTL)	Gene ↑	Cell-cycle/apoptosis	Human IVD tissue	Boyd et al., 2005
CDC28 protein kinase 2 (CKS2)	Gene ↑	Cell-cycle/apoptosis	Human IVD tissue	Boyd <i>et al.,</i> 2005
Growth arrest specific 1 (GAS1)	Gene ↑	Cell-cycle/apoptosis	Human IVD tissue	Boyd et al., 2005
Mucosa-associated lymphoid tissue translocation gene (MALT1)	Gene ↑	Cell-cycle/apoptosis	Human IVD tissue	Boyd <i>et al.,</i> 2005
ATPase Na ⁺ /K ⁺ transporting subunit alpha 1 (ATP1A1)	Gene ↑ Protein ↑	Cell-cycle/DNA synthesis	Bovine IVD	Mavrogonatou et al., 2015
Caspase 8 (CASP8)	Gene↓	Cell-cycle/apoptosis	Human IVD tissue	Boyd <i>et al.,</i> 2005
Rho-related BTB domain containing 1 (RHOBTB1)	Gene↓	Cell-cycle/apoptosis	Human IVD tissue	Boyd <i>et al.,</i> 2005
TNF-induced protein (GG2-1)	Gene↓	Cell-cycle/apoptosis	Human IVD tissue	Boyd <i>et al.,</i> 2005
AQP-3	Protein ↑	Cell membrane protein	Mouse NP cells	Palacio-Mancheno et al., 2017
TRPV4	Protein ↓	Cell membrane protein	Mouse NP cells	Palacio-Mancheno et al., 2017

several tissue types, such as kidney (Birder *et al.*, 2002; Vriens *et al.*, 2004), CNS (Liedtke and Friedman, 2003), smooth muscles (Muraki *et al.*, 2003) and others (Ueda *et al.*, 2011; Yang *et al.*, 2012), point towards the TRPV subfamily (especially TRPV4) as a potential cellular osmo- and volume-sensor involved in the

RVD mechanism (Becker *et al.*, 2005; Hdud *et al.*, 2014; Liedtke *et al.*, 2000; Pan *et al.*, 2008). Interestingly, Becker *et al.* (2005) demonstrate that TRPV4 play a key role in the cell-volume regulation by transiently transfecting CHO cells with TRPV4: CHO cell volume decreases after hypo-osmotic (200 mOsm/L)



Table 1b. Targets regulated by hyper-osmotic treatment. \uparrow = upregulation, \downarrow = downregulation. Only selected targets are discussed in the text.

Target gene (symbol)	Expression level change	Function	Model	Reference
MMP-2	Gene ↑	Enzyme-matrix turnover	Bovine NP cells (3D)	Neidlinger-Wilke et al., 2012
ADAMTS1	Gene ↑	Enzyme-matrix turnover	Human IVD tissue	Boyd <i>et al.,</i> 2005
Brain-derived neurotrophic factor (BDNF)	Gene ↑	Growth factor	Human IVD tissue	Boyd <i>et al.,</i> 2005
Muskelin (MKLN1)	Gene ↑	Growth factor	Human IVD tissue	Boyd <i>et al.,</i> 2005
Zinc finger protein 238 (ANF238)	Gene ↑	Growth factor	Human IVD tissue	Boyd <i>et al.,</i> 2005
IL-6	Gene↓	Growth factors/ cytokines	Human IVD tissue	Boyd <i>et al.,</i> 2005
Norrie disease protein/ Norrin (NDP)	Gene↓	Growth factors/ cytokines	Human IVD tissue	Boyd <i>et al.,</i> 2005
Homologous to mouse potassium-gated channel, Isk-related subfamily (KCNE4)	Gene ↑	Ion transport	Human IVD tissue	Boyd <i>et al.,</i> 2005
Solute carrier family 16 (monocarboxylic acid transporter) (SLC16A6)	Gene↓	Ion transport	Human IVD tissue	Boyd <i>et al.,</i> 2005
Solute carrier family 21 member 12 (SLC21A12)	Gene ↑	Ion transport	Human IVD tissue	Boyd <i>et al.,</i> 2005
Solute carrier family 4 member 11 (SLC4A11)	Gene ↑ Protein ↑	Ion transport	Bovine NP cells	Mavrogonatou <i>et al.,</i> 2015
Solute carrier family 5 member 3 (SLC5A3, SMIT1)	Gene ↑	Ion transport	Human IVD tissue	Boyd <i>et al.,</i> 2005
Solute carrier family 5 member 3 (SLC5A3, SMIT1)	Gene ↑ Protein ↑	Ion transport	Bovine NP cells	Mavrogonatou et al., 2015
Aggrecan (ACAN)	Gene ↑	IVD's ECM components	Bovine NP cells (3D), human NP and AF cells (3D)	Neidlinger- Wilke <i>et al.,</i> 2012; Wuertz <i>et al.,</i> 2007
Aggrecan (ACAN)	Gene↓ Protein↓	IVD's ECM components	Porcine NP in organ culture	Li et al., 2016
Biglycan (BGN)	Gene ↑	IVD's ECM components	Porcine TZ cells	Chen <i>et al.,</i> 2002
Biglycan (BGN)	Gene↓	IVD's ECM components	Porcine NP cells	Chen <i>et al.,</i> 2002



Table 1c. Targets regulated by hyper-osmotic treatment. \uparrow = upregulation, \downarrow = downregulation. Only selected targets are discussed in the text.

Target gene (symbol)	Expression level change	Function	Model	Reference
Collagen-1 (COL1A1)	Gene ↓	IVD's ECM components	Human NP, AF cells (3D)	Wuertz <i>et al.,</i> 2007
Collagen-2 (COL2A1)	Gene ↑	IVD's ECM components	Bovine AF cells (3D)	Wuertz <i>et al.,</i> 2007
Collagen-2 (COL2A1)	Gene↓Protein↓	IVD's ECM components	Porcine NP in organ culture	Li et al., 2016
Decorin (DCN)	Gene ↑	IVD's ECM components	Porcine TZ cells	Chen <i>et al.,</i> 2002
Decorin (DCN)	Gene↓	IVD's ECM components	Porcine NP cells	Chen <i>et al.,</i> 2002
Lumican (LUM)	Gene↓	IVD's ECM components	Porcine NP cells	Chen <i>et al.,</i> 2002
Ephrin-B2 (EFNB2)	Gene ↑	Signal transduction/ transcription	Human IVD tissue	Boyd <i>et al.,</i> 2005
Musculoapo-neurotic fibrosarcoma oncogene (MAF)	Gene ↑	Signal transduction/ transcription	Human IVD tissue	Boyd <i>et al.,</i> 2005
Nuclear receptor coactivator 3 (NCOA3)	Gene ↑	Signal transduction/ transcription	Human IVD tissue	Boyd <i>et al.,</i> 2005
Oncogene TC21 (RRAS2/TC21)	Gene ↑	Signal transduction/ transcription	Human IVD tissue	Boyd <i>et al.,</i> 2005
SOX9	Gene↓ Protein↓	Transcription factor	Porcine NP in organ culture	Li et al., 2016

treatment (RVD response after swelling), in contrast to untransfected CHO control cells. Hence, Becker et al. (2005) and others (Arniges et al., 2004; Phan et al., 2009) suggest that cell swelling caused by hypo-osmotic treatment leads to the generation of tension on the cell membrane and, thus, activation [= opening of a channel pore (Liu and Montell, 2015)] of the TRPV4 channel, which mediates the influx of extra-cellular Ca²⁺ that initiates a signalling cascades, causing an RVD response. TRP channels, including TRPV4, are expressed in the human, bovine and mouse IVD (Palacio-Mancheno et al., 2017; Sadowska et al., 2017; Walter et al., 2016). In the human IVD, hypo-osmotic conditions (200-334 mOsm/L) induce an up-regulation of TRPV4 (on the protein level), leading to an activated calcium influx (Walter et al., 2016). In contrast, hyper-osmolarity (530 mOsm/L), combined with cyclic loading (10 min on and off for 1.5 h/d), significantly downregulates TRPV4 expression (mouse NP cells) (Palacio-Mancheno et al., 2017). Moreover, the expression and/or activity of TRPV4 is modulated by the inflammation (upregulated cytokines IL-6 and IL-1 β) and correlates with pro-inflammatory cytokines in the IVD and cartilage (Clark *et al.*, 2010; Phan *et al.*, 2009; Sadowska *et al.*, 2017; Walter *et al.*, 2016). Therefore, Walter *et al.* (2016) suggest that alternations in TRPV4mediated sensation of osmotic changes (also known as osmosensing) could aid the progression of disc degeneration. Additionally, both TRPV4-mediated osmotic and inflammatory signals may be regulated through the p38/MAPK and ERK1/2 pathways (Chen *et al.*, 2013; Hdud *et al.*, 2014; Qu *et al.*, 2016).

AQPs are small transmembrane channel proteins responsible for water transport and are of relevance in osmoregulation. The presence of AQPs is confirmed in the healthy human NP (Richardson *et al.*, 2008), with decreased expression during degeneration as an adaptive mechanism demonstrated in various species: rat NP and AF (Tas *et al.*, 2012), rabbit NP (Wang and Zhu, 2011), human NP (Hoffman *et al.*, 2017; Johnson *et al.*, 2015). These findings are in line



with the observed downregulation of AQP-1 under reduced osmolarity [rabbit NP (Wang and Zhu, 2011)] and the increased expression of AQP-3 under hyperosmotic conditions [mouse NP (Palacio-Mancheno *et al.*, 2017)] and consequent NP maturation (but without changes in AQP-1). Furthermore, TRPV4 and AQP-4 interact and form a channel complex (in astrocytes), which might constitute an important link in the cell volume homeostasis by integrating water transport and calcium signalling (at least in the CNS) (Benfenati *et al.*, 2011; Jo *et al.*, 2015).

Additionally, AQPs might play a role in inflammation in the IVD and cartilage (Haneda et al., 2018; Takeuchi et al., 2018; Xie et al., 2016). In human chondrocytes, AQP-1 co-localises (on the protein level, as shown by immunofluorescence) with the catabolic factor ADAMTS-4 (an aggrecan-degrading enzyme involved in IVD and cartilage degeneration) and a downregulation of AQP-1 decreases the expression of ADAMTS-4 (Haneda et al., 2018; Sun et al., 2015). Additionally, a knockdown of AQP-9 (human chondrocytes) decreases the mRNA levels of other catabolic factors (Takeuchi *et al.*, 2018). On the other hand, an overexpression of AQP-3 (human degenerated NP cells) decreases the expression of ADAMTS 4 and 5 and suppresses the Wnt/ β -catenin signalling (Xie *et al.*, 2016), which is involved in IVD cell senescence (Hiyama et al., 2010b; Hiyama et al., 2011; Wang et al., 2012). These findings suggest a protective role of AQP-3 against disc degeneration (Xie *et al.*, 2016). Yet, in corneal epithelial cells, hyperosmotic treatment (450, 500 and 550 mOsm/L) induces the upregulation of AQP-5 (via JNKs pathway), leading to an upregulation of IL-1 β , IL-6, IL-8, TNF- α and caspase-1 (Ren et al., 2017), with similar findings in cartilage (Cai et al., 2017) and IVD (Hoffman et al., 2017; Snuggs et al., 2017).

Cell responses to osmotic changes: target genes and signalling pathways

Cellular responses to changes in the osmotic environment are facilitated through multiple signalling mediators, including TonEBP/NFAT5, also known as OREBP, or signal-transduction pathways, such as p38/MAPK, ERK and JNK pathways (Aramburu and Lopez-Rodriguez, 2009; Dong et al., 2014; Hdud et al., 2014; Li et al., 2016; Ren et al., 2017; Sheikh-Hamad and Gustin, 2004). These mediators do not only play a role in the cell volume regulatory mechanisms, but also initiate changes in other cellular processes, such as cell survival, matrix turnover and inflammation (Table 1a-c, Fig. 1). Hence, the osmotic challenge and accompanying altered gene expression can contribute to the development and/ or progression of the inflammatory responses in the IVD. However, the inflammation in the IVD is much more complex than how it is presented in the context of the IVD's osmotic environment (present review) and is reviewed by Molinos *et al.* (2015). Briefly, inflammation can occur within the IVD, despite the IVD being immune-privileged (in a healthy state), as NP cells produce pro-inflammatory cytokines, while macrophages infiltrating the damaged IVD can further exacerbate the inflammation (Molinos *et al.*, 2015).

One of the most prominent signal transduction pathways that facilitates mammalian cell responses to numerous extracellular signals is the MAPK family. Three major members of the MAPK family are ERK, JNK and p38, which can be activated by multiple stimuli, such as growth factors (Hiyama et al., 2010a; Uchiyama et al., 2007), inflammatory cytokines (Klawitter et al., 2012) and osmotic stress (Li et al., 2017). Activation of each of these pathways controls several cellular functions, including cell cycle progression (ERK), cell proliferation and survival (JNK), cell growth, cell differentiation, cell death, inflammation and matrix catabolism (p38) (Johnson and Lapadat, 2002; Studer et al., 2007; Yang et al., 2016). In this review, each signal-transduction pathway is presented in the context of the IVD cell response to osmotic stress. However, these signalling pathways are also activated by different stimuli and can induce a range of cell responses not necessarily addressed within this review (Wong, 2009). In the IVD, a hyper-osmotic treatment (500 and 600 mOsm/L) participates in the activation of the p38 pathway in bovine and rabbit NP cells (Dong et al., 2014; Mavrogonatou and Kletsas, 2009) and results in the ATM-mediated phosphorylation of p53 in response to DNA damage caused by hyper-osmotic shock (Kishi et al., 2001; Mavrogonatou and Kletsas, 2009). However, MAPK activation and signalling are cell-type specific, with JNK activation occurring upon hypo-osmotic stimulation in IVD cells and upon hyper-osmotic stimulation in chondrocytes (Racz et al., 2007). Furthermore, conflicting activation triggers are described for the ERK pathway, with authors reporting distinctive osmotic conditions for both activation and inhibition. These differences may arise from i) using different animal models and different definition of osmolarity levels (hypo-, iso- and hyper-osmotic values), ii) adjusting the osmolarity with various agents and iii) using different culture conditions, e.g. supplementation with growth factors (Mavrogonatou and Kletsas, 2010). Activation of the ERK pathway under hyper-osmotic stress is observed in rabbit NP cells treated with 500-600 mOsm/L of medium adjusted with NaCl (Dong et al., 2014), rat NP cells treated with 450 mOsm/L of medium (adjusting agent unknown) (Tsai et al., 2007) and bovine NP cells treated with 500 mOsm/L of medium adjusted with urea (Mavrogonatou and Kletsas, 2012). In rat NP cells, ERK phosphorylation leads to the activation of TonEBP/NFAT5 (Tsai et al., 2007) - an adaptation factor to high osmotic stress that protects IVD cells from undergoing apoptosis (Tsai et al., 2006; Tsai et al., 2007). In contrast, ERK inhibition can



Table 2. Targets regulated by hypo-osmotic treatment. ↑ = upregulation, ↓ = downregulation. Only selected targets are discussed in the text.

Target gene (symbol)	Expression level change	Function	Model	Reference
AQP-1	Protein↓	Cell membrane proteins	Rabbit NP cells	Wang and Zhu, 2011
TRPV4	Receptor function (tyrosine phosphorylation) ↑	Cell membrane proteins	HEK293	Vriens <i>et al.,</i> 2004; Xu <i>et al.,</i> 2003
TRPV4	Protein ↑	Cell membrane proteins	Equine chondrocytes	Hdud <i>et al.,</i> 2014
TRPV4	Protein ↑	Cell membrane proteins	Human IVD	Walter <i>et al.,</i> 2016
Large-conductance Ca ²⁺ - activated K ⁺ (BK _{Ca})	Protein ↑	Cell membrane proteins	Equine chondrocytes	Hdud <i>et al.,</i> 2014
MMP3	Gene ↑	Enzyme-matrix turnover	Bovine NP cells (3D)	Neidlinger- Wilke <i>et al.,</i> 2012
Collagen-2 (COL2A1)	Gene ↑	IVD's ECM components	Porcine TZ cells	Chen <i>et al.,</i> 2002
Collagen-2 (COL2A1)	Gene↓ Protein↓	IVD's ECM components	Porcine NP in organ culture	Li et al., 2016
Aggrecan (ACAN)	Gene ↑	IVD's ECM components	Porcine TZ cells	Chen <i>et al.,</i> 2002
Aggrecan (ACAN)	Gene↓ Protein↓	IVD's ECM components	Porcine NP in organ culture	Li et al., 2016
Biglycan (BGN)	Gene ↑	IVD's ECM components	Porcine TZ cells	Chen <i>et al.,</i> 2002
Decorin (DCN)	Gene ↑	IVD's ECM components	Porcine TZ cells	Chen <i>et al.,</i> 2002
Lumican (LUM)	Gene↓	IVD's ECM components	Porcine NP cells	Chen <i>et al.,</i> 2002
Tubulin (TUB)	Gene↓	IVD's ECM components	Porcine NP cells	Chen <i>et al.,</i> 2002
ERK1/2	Protein ↑	Signaling pathway	Equine chondrocytes	Hdud <i>et al.,</i> 2014
SOX9	Gene↓ Protein↓	Transcription factor	Porcine NP in organ culture	Li <i>et al.,</i> 2016

lead to the suppression of TonEBP/NFAT5 and the augmentation of cell apoptosis [NP cells in a porcine disc culture (Li *et al.*, 2017), rat NP cells (Tsai *et al.*, 2007), rabbit NP cells (Dong *et al.*, 2014)]. Activation of p38 and JNK induces cell apoptosis [rabbit NP cells (Dong *et al.*, 2014)], indicating the involvement of these pathways in the degenerative shift under hyper-osmotic conditions. This is in line with the study by Haschtmann *et al.* (2006), in which, following a hyper-osmotic treatment (485 mOsm/L), cells (rabbit IVD in organ culture) exhibit a reversible drop in

viability. Moreover in the IVD, the ERK pathway controls the expression of collagen type II (Chen *et al.*, 2002; Wuertz *et al.*, 2007) and MMP-2 (Neidlinger-Wilke *et al.*, 2012), while collagen type I (Wuertz *et al.*, 2007), IL-6 (Boyd *et al.*, 2005) and MMP-3 (Neidlinger-Wilke *et al.*, 2012) are identified as targets of the p38/ MAPK pathway (Jung *et al.*, 2017; Park *et al.*, 2016; Sano *et al.*, 2001). However, aggrecans are regulated by both pathways: in bovine NP cells, lactoferricininduced upregulation of aggrecan mRNA levels are decreased when p38/MAPK and ERK pathways are



inhibited by SD203580 and PD98059, respectively (Kim *et al.*, 2012). In a study by Tsirimonaki *et al.* (2013), prolonged activation of the ERK1/2 pathway increases the mRNA expression level of aggrecan in human NP cells. On the contrary, leptin-induced p38 phosphorylation upregulates aggrecanases and downregulates aggrecan on the gene and protein level in human NP cells (Li *et al.*, 2014b). Another signalling pathway that could be involved in the IVD's osmo-adaptation, but has not been investigated thus far, is the non-canonical PKC pathway. Increased activity of the PKC pathway is involved in the regulation of aggrecan expression, matrix synthesis and cell proliferation (Arai *et al.*, 2012; Rottmar *et al.*, 2014; Tsirimonaki *et al.*, 2013) in rat and human NP cells, as well as bovine chondrocytes, and may be involved in Ca²⁺-mediated activation of the TRPV4 channel (Fan *et al.*, 2009; Xu *et al.*, 2003), which is linked to IVD osmosensing (Walter *et al.*, 2016).

One of the key cellular osmoregulative mediators is TonEBP/NFAT5, which modulates the expression of genes induced by osmotic stress. In response to hyper-osmotic challenges and upon the activation of the ERK and p38-MAPK pathways, TonEBP/NFAT5 accumulates in the cell nucleus (Ho, 2006; Tsai *et al.*, 2007) (Fig. 1). Consequently, it induces the expression of genes that are involved in the production of organic osmolytes (to counterbalance the osmotic challenge) (Lee *et al.*, 2011b), aggrecan (Tsai *et al.*, 2006) and the pro-inflammatory cytokines IL-1 β and TNF- α




Fig. 1. Osmolarity-related changes in the IVD cells. Schematic representation of the IVD response to the osmotic stimuli. Changes in cell volume (top left: cell shrinkage under an hyper-osmotic challenge; top right: cell swelling under an hypo-osmotic challenge) trigger the activation of volume recovery mechanisms (RVI and RVD) to restore the homeostasis but can also act as stress signals, activating cell membrane receptors. TRP channels, AQPs, SLCs and ASICs are membrane proteins with a potentially crucial role in osmosensing and osmo-adaptation. Transduced signals activate the MAPKs pathway (middle). Further, osmolarity changes lead to increase in NFAT nuclear shuttling, which induces transcription of genes involved in matrix homeostasis and pro-inflammatory cytokines (bottom middle). These changes may activate a positive/negative feedback loop to the osmo-receptor and/or signalling pathways. However, the exact and complete osmosensing pathway has not been yet extensively studied in the disc.



(Johnson et al., 2017; Lee et al., 2008; Trama et al., 2002), which have known implications in IVD degeneration (Lee et al., 2011a; Risbud and Shapiro, 2014; Sadowska et al., 2017). In the IVD, hyper-osmotic stress is not the only regulator of the TonEBP/NFAT5 complex. The expression and activity of TonEBP/NFAT5, which is calcium-dependent (Choi et al., 2018; Hiyama *et al.*, 2009), can be also regulated by growth factors, such as BMP-2 and TFG- β (Halterman *et* al., 2012; Hiyama et al., 2010a). These multimodal activation mechanisms indicate that TonEBP/NFAT5 is critical not only for osmoregulation, but also for other cellular functions (e.g. cell survival, matrix synthesis, etc.). TonEBP/NFAT5 modulates the NF- κ B pathway, which is a pivotal element in the cellular response to inflammation and stress, with downstream targets including TNF- α , IL-1 β , IL-6 and IL-8 (Lopez-Rodriguez et al., 2001; Roth et al., 2010; Tak and Firestein, 2001). The NF-кВ pathway is implicated in many chronic conditions such as osteoarthritis (Makarov, 2001), osteoporosis (Kim et al., 2006) and IVD degeneration (Nasto et al., 2012; Xu et al., 2015; Zhongyi et al., 2015). Changes in cell volume, triggered by hyper-osmotic conditions and sensed by an osmosensing channel (e.g. TRP), can be perceived by a cell as a stress signal. Such a signal can initiate a pro-inflammatory cascade via the ROS-mediated activation of the NF-κB (and/ or p38/MAPK) pathway (Abolhassani et al., 2008; Panahi et al., 2018; Rajamaki et al., 2016; Schwartz et al., 2009) and activate the NLRP3 inflammasome - a protein complex, downstream targets of which are caspase-1 and IL-1 β (Chen *et al.*, 2015). In various cell types, activation of the NLRP3 inflammasome during RVD mechanisms leads to the activation of the pro-inflammatory cytokine IL-1β (Compan et al., 2012; Compan and Pelegrin, 2018; Ip and Medzhitov, 2015). Interestingly, a positive relationship between the expression of NLRP3, IL-1 β and the IVD degeneration grade exists (NP tissue, mRNA and protein level) (Chen et al., 2015; Song et al., 2017). This indicates that NLRP3 may constitute a putative target between the altered osmotic environment and the inflammation and, thus, be a possible therapeutic target for the treatment of IVD degeneration (Tang

et al., 2018). ASICs are proton-activated cation channels (Yoder *et al.*, 2018) that are hypothesised to be of functional importance in IVD osmoprotection and pathophysiology (Li *et al.*, 2014a; Uchiyama *et al.*, 2008; Yuan *et al.*, 2016) by facilitating the adaptation of IVD cells (rodent) to an acidic and/or hyper-osmotic environment *via* the ERK signalling pathway (Uchiyama *et al.*, 2007). The presence of ASIC is also confirmed on the mRNA and protein level in healthy and degenerated human IVD tissue (Cuesta *et al.*, 2014), with higher expression levels during IVD degeneration, possibly due to changes in pH and hydrostatic pressure (Cuesta *et al.*, 2014). The viability of rat NP cells cultured in hyperosmotic (450 mOsm/L) medium decreases in a dosedependent manner (from ~ 100 % to ~ 40 %) when the ASIC3 inhibitor amiloride (10-100 µM, 24 h, MTT) is added (Uchiyama et al., 2007). However, the same study shows that increasing the osmolarity from 330 to 450 mOsm/L, without the ASIC3 inhibitor, does not have a significant influence on NP cells viability (Uchiyama et al., 2007). In the context of the IVD and osmoregulation, an acidic pH (which is a characteristic of the degenerated IVD) downregulates the synthesis of PGs, thereby contributing to low extracellular osmolarity (Ohshima and Urban, 1992; Wuertz et al., 2009). The altered expression of ASICs can, on the one hand, indicate a causative and hence detrimental role in IVD degeneration or may, on the other hand, constitute a mechanism to better cope with the degenerative conditions (Uchiyama et al., 2007).

Therapeutic modulation of osmosensing

Dysregulated tissue osmolarity is a hallmark of several chronic diseases, suggesting that the efficiency of the body's osmoprotective mechanisms decreases with age and/or tissue degeneration (Brocker *et al.*, 2012). Non-physiological concentrations of intra- and extra-cellular structural molecules and signalling mediators alter the cellular responses to otherwise normal stimuli, such as physiological loading. A healthy IVD could be described by its ability to effectively adapt to diurnal osmotic changes and auto-regulate itself, without damage (Sivan et al., 2006). From this perspective, a deviation into extreme osmotic conditions (either hyper- or hypo-osmotic), concomitant with a decreased adaptation ability, can have detrimental consequences on the IVD. Osmotic stress can be potentially counteracted by promoting osmoadaptation through stimulation of cellular defence mechanisms (Johnson et al., 2014) or by combating the consequences of a dysregulated osmosensing (van Dijk et al., 2015).

A key intracellular mediator of osmoadaptation is the transcription factor TonEBP/NFAT5, which controls the expression of genes involved in the response to hyper-osmolarity (Lopez-Rodriguez et al., 2004) and supports cell survival, especially in tissues regularly experiencing hyper-osmotic stress (Choi et al., 2018; Gajghate et al., 2009; Tsai et al., 2006; Tsai et al., 2007). Therefore, stimulating and promoting TonEBP/NFAT5 could have beneficial effects on the IVD homeostasis in a situation when the osmotic balance or the cell's adaptation capability are disturbed. Adaptation of rat NP cells to hyperosmolarity is mediated via ERK- and p38-induced activation of TonEBP/NFAT5 (Tsai et al., 2007), which regulates water balance through expression of several target genes [e.g. AQPs (Gajghate et al., 2009)]. In rat NP cells, dominant negative NFAT5 significantly reduces cell viability and activated caspase 3,



suggesting a pro-survival role of TonEBP/NFAT5 in hyper-osmotic conditions (Tsai et al., 2006). The osmoprotective activity of TonEBP/NFAT5 could be therapeutically enhanced; however, TonEBP/NFAT5 also participates in pro-inflammatory responses in the IVD (Johnson et al., 2017). Therefore, the desired TonEBP/NFAT5-modulating compounds should ideally reduce its potential chronic pro-inflammatory effect, while enhancing its osmoprotective activity. TonEBP/NFAT5 inhibitors that selectively suppress the expression of pro-inflammatory genes without hampering TonEBP/NFAT5-induced osmoadaptation are developed and tested in a model of chronic arthritis, representing the first steps in this direction (Han et al., 2017). The molecular signals directing TonEBP/NFAT5 towards osmoadaptation and/or inflammation in IVD cells are currently unknown. For example, in macrophages, the putative sensors that discriminate between pro-inflammatory and osmoprotective effects of TonEBP/NFAT5 are the ROS (Kim et al., 2013). Among other functions, TonEBP/ NFAT5 positively regulates synthesis and transport of osmolytes, gene expression of AQPs and synthesis of extracellular matrix components, all of which could be possibly therapeutically enhanced.

Organic osmolytes are solutes (e.g. sugars, polyols, amino acids) that protect biomolecules from the damage caused by changing osmotic pressure and dehydration and, thereby, provide cytoprotection and anti-inflammatory effects (Rabbani and Choi, 2018). Natural osmolytes participate in regenerating native protein forms from unfolded states, restoring proper protein functions and, thus, possibly preventing disease development (Alfieri *et al.*, 2002). Physiological concentrations of osmolytes in the IVD and their effects in and outside IVD cells have not yet been thoroughly investigated (Mavrogonatou and Kletsas, 2012). Synthesis and uptake of osmolytes in the IVD can be possibly regulated by TonEBP/ NFAT5-COX-2-PGE2 signalling, as an osmoprotective role is demonstrated for this pathway (Favale et al., 2009; Kim et al., 2009). In renal cells subjected to hyper-osmolarity, COX-2 is involved in the accumulation of osmolytes (Moeckel et al., 2003) and COX-2 inhibition reduces cell viability (Neuhofer et al., 2004). Interestingly, a recent study testing TonEBP/NFAT5 in mouse hyper-osmotic IVD organ cultures shows that TonEBP/NFAT5 also provides cytoprotective effects in the IVD by inducing COX-2 (Choi et al., 2018). In view of these findings, currently used COX-2-targeting drugs could impair IVD osmoadaptation mechanisms (Bonner et al., 2009) and further contribute to the pathophysiology of DDD. Therapeutic enhancement of osmolyte function by a COX-2-unrelated mechanism could potentially increase resistance of the IVD to osmotic stress.

Dysfunction or aberrant expression of various AQPs is likely implicated in the pathogenesis of IVD degeneration. Inducing the expression and/or activity of certain AQPs can promote an exchange of fluids in

the NP, possibly reducing the progression of DDD. Both water permeability and ionic conductance of AQPs can be positively regulated by PKC (Zhang *et al.*, 2007) and cyclic nucleotides (Lorenz *et al.*, 2003). However, these molecules control numerous cellular processes and their therapeutic modulation might produce detrimental off-target effects (Cooke *et al.*, 2017). Specific upregulation of AQP gene expression could be achieved by CRISPR gene editing, *e.g.* using dCas fused with VP64 domains targeted to AQP gene enhancers (Konermann *et al.*, 2015).

As a membrane receptor, TRPV4 could potentially be regulated by specific agonists or antagonists, to prevent an age-related loss of ECM and reduce inflammation in the IVD (Walter et al., 2016). However, involvement of TRPV4 in these processes is rather complex and a tight balance in the expression/ regulation of TRPV4 is crucial in the maintenance of the musculoskeletal health. As an example, blocking TRPV4 with the antagonist GSK205 reduces chondrocyte responses to hypo-osmotic stress, including RVD and production of PGE2 (porcine cells) (Phan *et al.*, 2009), while activating TRPV4 with 4α PDD inhibits the production of the pro-inflammatory mediator nitric oxide in rat chondrocytes (Hu et al., 2013). The importance of a balance in TRPV4 expression/function is also shown in mouse models, where loss of TRPV4 leads to a progressive osteoarthritic joint degeneration (Clark et al., 2010), while gain of function causes various skeletal dysplasias (Mah et al., 2016; Weinstein et al., 2014). Therefore, therapeutic TRPV4 agonists or antagonists should be specific [e.g. 4α -PDD or GSK2193874, respectively (McNulty et al., 2015)], used locally (e.g. injections) and only once the benefits of modulating TRPV4 have been clearly demonstrated. Stable overexpression or knock-out of TRPV4 could be delivered into the IVD, e.g. in genetically engineered therapeutic cells.

Other therapeutic approaches could include augmentation of extracellular matrix, *e.g.* by upregulating glucuronosyltransferase 1, a key TonEBP/ NFAT5-dependent regulator of glycosaminoglycan synthesis (Hiyama *et al.*, 2009), or by implanting biomaterials. Osmoprotective moieties, such as chondroitin sulphate, can be incorporated into injectable hydrogels to increase hydration of the synthetic matrix in tissue engineering applications (Chen *et al.*, 2016; Farnsworth *et al.*, 2014).

Conclusion and outlook

Changes in the IVD hydration and osmolarity ranging from ~ 430 (iso-osmotic) to ~ 496 mOsm/L (hyperosmotic) can be observed during daily life activities. From this perspective, the osmotic environment in the IVD is unusual, as the osmotic range which is physiological for the IVD would be considered high



for other tissues (e.g. blood plasma with osmolarity of ~ 300 mOsm/L). However, a reduction in tissue osmolarity to ~ 300 mOsm/L (hypo-osmotic) is a consequence of a cascade of degenerative changes and a hallmark of IVD degeneration. In this review, an overview of the existing studies on IVD osmolarity, its potential intersection with IVD inflammation and how this knowledge could be translated into treatment strategies is presented. Increasing scientific evidence points towards a crucial role of ion channels (such as TRP channels) in the regulatory volume control mechanisms in the IVD, as well as in cartilage – a tissue with similar characteristics to the NP tissue. Simultaneously, AQPs are an emerging target involved not only in osmosensing, but also in IVD degeneration and inflammation. Importantly, TonEBP/NFAT5 (co-activated by calcium and ERK/ p38 signalling) facilitates the IVD adaptation to fluctuations of its osmotic environment. Changes in water and ion concentrations affect the homeostasis of the IVD, as indicated by dysregulation of ECM synthesis under hypo- and hyper-osmotic conditions, but many details on the underlying mechanisms are still unknown. Several questions remain to be answered, such as:

- What is the underlying mechanism of the RVD and RVI response in NP and AF cells?
- What is the mechanistic function of cell membrane carriers and ion channels in IVD osmosensing and osmoadaptation?
- Do the cell membrane carriers and ion channels interact in the IVD?
- Can the activation of PKC and NF-*k*B pathways be osmolarity-induced?
- What is the role of these pathways in osmoadaptation and/or osmolarity-induced inflammation?

A broader understanding of how IVD cells react to altered osmolarity, e.g. in relation to PG synthesis, cell survival/apoptosis or inflammation, is crucial when aiming to advance the current concepts of IVD pathophysiology. Once these mechanisms are better understood and possible targets are identified, suitable therapeutics that successfully and specifically modulate osmoadaptation can be developed. This new class of anti-inflammatory and regenerative therapeutics may target the osmoprotective transcription factor TonEBP/NFAT5 or osmo-sensing membrane proteins such as TRPV4 or AQPs. Gene editing techniques (e.g. CRISPR/Cas) can be used to modulate the expression/activity of osmosensing-associated genes in locally delivered autologous therapeutic cells. For example, genes regulating the activity of osmosensors or synthesis and transport of osmolytes can be activated by dCas fused with VP64 domains or switched off by Cas-mediated knock-out/knock-down. Antiinflammatory and regenerative therapeutics may be combined with gene editing techniques, with the overall aim of maintaining proper function of the cellular osmoadaptation sensors and the ECM and to ensure efficient transport of water and solutes through loaded IVD tissue.

References

Abolhassani M, Wertz X, Pooya M, Chaumet-Riffaud P, Guais A, Schwartz L (2008) Hyperosmolarity causes inflammation through the methylation of protein phosphatase 2A. Inflamm Res **57**: 419-429.

Alam K, Pahwa S, Wang X, Zhang P, Ding K, Abuznait AH, Li L, Yue W (2016) Downregulation of organic anion transporting polypeptide (OATP) 1B1 transport function by lysosomotropic drug chloroquine: implication in OATP-mediated drugdrug interactions. Mol Pharm **13**: 839-851.

Alfieri RR, Cavazzoni A, Petronini PG, Bonelli MA, Caccamo AE, Borghetti AF, Wheeler KP (2002) Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis. J Physiol **540**: 499-508.

Alfredo Franco-Obregón HK, Greutert H, Wernas T, Egli M, Cambria E, Sekiguchi M, Boos N, Hausmann O, Ferguson S, Wuertz-Kozak K (2017) The balance of transient receptor potential channel TRPC6 to TRPC1 determines ageing and mechanotransduction in intervertebral disc cells Conference Proceeding, ORS PSRS 4th International Spine Research Symposium, Split Rock Resort, PA, USA.

Appelboom JW, Brodsky WA, Dennis WH, Diamond I, Miley JF, Rehm WS (1956) The freezing point depression of mammalian tissues in relation to the question of osmotic activity of cell fluid. J Gen Physiol **40**: 183-199.

Arai F, Hiyama A, Sakai D, Yokoyama K, Mochida J (2012) The expression and role of non-canonical (PKC) signaling in nucleus pulposus cell metabolism. J Orthop Res **30**: 1478-1485.

Aramburu J, Lopez-Rodriguez C (2009) Brx shines a light on the route from hyperosmolarity to NFAT5. Sci Signal **2**: pe20.

Arniges M, Vazquez E, Fernandez-Fernandez JM, Valverde MA (2004) Swelling-activated Ca2+ entry *via* TRPV4 channel is defective in cystic fibrosis airway epithelia. J Biol Chem **279**: 54062-54068.

Arroyo JP, Kahle KT, Gamba G (2013) The SLC12 family of electroneutral cation-coupled chloride cotransporters. Mol Aspects Med **34**: 288-298.

Baltz JM (2012) Media composition: salts and osmolality. Methods Mol Biol **912**: 61-80.

Becker D, Blase C, Bereiter-Hahn J, Jendrach M (2005) TRPV4 exhibits a functional role in cell-volume regulation. J Cell Sci **118**: 2435-2440.

Belavy DL, Albracht K, Bruggemann GP, Vergroesen PP, van Dieen JH (2016) Can exercise positively influence the intervertebral disc? Sports Med **46**: 473-485.



Belavy DL, Quittner MJ, Ridgers N, Ling Y, Connell D, Rantalainen T (2017) Running exercise strengthens the intervertebral disc. Sci Rep **7**: 45975.

Benfenati V, Caprini M, Dovizio M, Mylonakou MN, Ferroni S, Ottersen OP, Amiry-Moghaddam M (2011) An aquaporin-4/transient receptor potential vanilloid 4 (AQP4/TRPV4) complex is essential for cell-volume control in astrocytes. Proc Natl Acad Sci U S A **108**: 2563-2568.

Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang E, Ruiz G, De Groat WC, Apodaca G, Watkins S, Caterina MJ (2002) Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci **5**: 856-860.

Bonner JS, Anderson BM, Blevins J, Kempson SA (2009) Aspirin impairs transport of protective osmolytes in renal inner medullary collecting duct cells. Open Urol Nephrol J **2**: 6-10.

Boyd LM, Richardson WJ, Chen J, Kraus VB, Tewari A, Setton LA (2005) Osmolarity regulates gene expression in intervertebral disc cells determined by gene array and real-time quantitative RT-PCR. Ann Biomed Eng **33**: 1071-1077.

Brocker C, Thompson DC, Vasiliou V (2012) The role of hyperosmotic stress in inflammation and disease. Biomol Concepts **3**: 345-364.

Cai L, Lei C, Li R, Chen WN, Hu CM, Chen XY, Li CM (2017) Overexpression of aquaporin 4 in articular chondrocytes exacerbates the severity of adjuvantinduced arthritis in rats: an *in vivo* and *in vitro* study. J Inflamm (Lond) **14**: 6. DOI: 10.1186/s12950-017-0153-8.

Cassinelli EH, Hall RA, Kang JD (2001) Biochemistry of intervertebral disc degeneration and the potential for gene therapy applications. Spine J **1**: 205-214.

Chen F, Yu S, Liu B, Ni Y, Yu C, Su Y, Zhu X, Yu X, Zhou Y, Yan D (2016) An injectable enzymatically crosslinked carboxymethylated pullulan/chondroitin sulfate hydrogel for cartilage tissue engineering. Sci Rep **6**: 20014.

Chen J, Baer AE, Paik PY, Yan W, Setton LA (2002) Matrix protein gene expression in intervertebral disc cells subjected to altered osmolarity. Biochem Biophys Res Commun **293**: 932-938.

Chen Y, Williams SH, McNulty AL, Hong JH, Lee SH, Rothfusz NE, Parekh PK, Moore C, Gereau RW 4th, Taylor AB, Wang F, Guilak F, Liedtke W (2013) Temporomandibular joint pain: a critical role for Trpv4 in the trigeminal ganglion. Pain **154**: 1295-1304.

Chen ZH, Jin SH, Wang MY, Jin XL, Lv C, Deng YF, Wang JL (2015) Enhanced NLRP3, caspase-1, and IL- 1beta levels in degenerate human intervertebral disc and their association with the grades of disc degeneration. Anat Rec (Hoboken) **298**: 720-726.

Choi H, Chaiyamongkol W, Doolittle AC, Johnson ZI, Gogate SS, Schoepflin ZR, Shapiro IM, Risbud MV (2018) COX-2 expression mediated by calcium-TonEBP signaling axis under hyperosmotic conditions serves osmoprotective function in nucleus pulposus cells. J Biol Chem **293**: 8969-8981. Clark AL, Votta BJ, Kumar S, Liedtke W, Guilak F (2010) Chondroprotective role of the osmotically sensitive ion channel transient receptor potential vanilloid 4: age- and sex-dependent progression of osteoarthritis in Trpv4-deficient mice. Arthritis Rheum **62**: 2973-2983.

Compan V, Baroja-Mazo A, Lopez-Castejon G, Gomez AI, Martinez CM, Angosto D, Montero MT, Herranz AS, Bazan E, Reimers D, Mulero V, Pelegrin P (2012) Cell volume regulation modulates NLRP3 inflammasome activation. Immunity **37**: 487-500.

Compan V, Pelegrin P (2018) Methods to study cell swelling-induced inflammasome activation. Methods Mol Biol **1714**: 191-197.

Cooke M, Magimaidas A, Casado-Medrano V, Kazanietz MG (2017) Protein kinase C in cancer: the top five unanswered questions. Mol Carcinog **56**: 1531-1542.

Cuesta A, Del Valle ME, Garcia-Suarez O, Vina E, Cabo R, Vazquez G, Cobo JL, Murcia A, Alvarez-Vega M, Garcia-Cosamalon J, Vega JA (2014) Acid-sensing ion channels in healthy and degenerated human intervertebral disc. Connect Tissue Res **55**: 197-204.

Dawson DC (1988) Water movement through lipid bilayers, pores, and plasma membranes: theory and reality. Science **240**: 228-229.

Dong ZH, Wang DC, Liu TT, Li FH, Liu RL, Wei JW, Zhou CL (2014) The roles of MAPKs in rabbit nucleus pulposus cell apoptosis induced by high osmolality. Eur Rev Med Pharmacol Sci **18**: 2835-2845.

Erwin WM, Hood KE (2014) The cellular and molecular biology of the intervertebral disc: a clinician's primer. J Can Chiropr Assoc **58**: 246-257.

Fan HC, Zhang X, McNaughton PA (2009) Activation of the TRPV4 ion channel is enhanced by phosphorylation. J Biol Chem **284**: 27884-27891.

Farnsworth NL, Mead BE, Antunez LR, Palmer AE, Bryant SJ (2014) Ionic osmolytes and intracellular calcium regulate tissue production in chondrocytes cultured in a 3D charged hydrogel. Matrix Biol **40**: 17-26.

Favale NO, Casali CI, Lepera LG, Pescio LG, Fernandez-Tome MC (2009) Hypertonic induction of COX2 expression requires TonEBP/NFAT5 in renal epithelial cells. Biochem Biophys Res Commun **381**: 301-305.

Gajghate S, Hiyama A, Shah M, Sakai D, Anderson DG, Shapiro IM, Risbud MV (2009) Osmolarity and intracellular calcium regulate aquaporin2 expression through TonEBP in nucleus pulposus cells of the intervertebral disc. J Bone Miner Res **24**: 992-1001.

Guilak F, Ting-Beall HP, Baer AE, Trickey WR, Erickson GR, Setton LA (1999) Viscoelastic properties of intervertebral disc cells. Identification of two biomechanically distinct cell populations. Spine (Phila Pa 1976) **24**: 2475-2483.

Halterman JA, Kwon HM, Wamhoff BR (2012) Tonicity-independent regulation of the osmosensitive transcription factor TonEBP (NFAT5). Am J Physiol Cell Physiol **302**: C1-8.



Han EJ, Kim HY, Lee N, Kim NH, Yoo SA, Kwon HM, Jue DM, Park YJ, Cho CS, De TQ, Jeong DY, Lim HJ, Park WK, Lee GH, Cho H, Kim WU (2017) Suppression of NFAT5-mediated inflammation and chronic arthritis by novel kappaB-binding inhibitors. EBioMedicine **18**: 261-273.

Haneda M, Hayashi S, Matsumoto T, Hashimoto S, Takayama K, Chinzei N, Kihara S, Takeuchi K, Nishida K, Kuroda R (2018) Depletion of aquaporin 1 decreased ADAMTS4 expression in human chondrocytes. Mol Med Rep **17**: 4874-4882.

Haschtmann D, Stoyanov JV, Ferguson SJ (2006) Influence of diurnal hyperosmotic loading on the metabolism and matrix gene expression of a wholeorgan intervertebral disc model. J Orthop Res **24**: 1957-1966.

Hdud IM, Mobasheri A, Loughna PT (2014) Effect of osmotic stress on the expression of TRPV4 and BKCa channels and possible interaction with ERK1/2 and p38 in cultured equine chondrocytes. Am J Physiol Cell Physiol **306**: C1050-1057.

Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch **447**: 465-468.

Hiyama A, Gajghate S, Sakai D, Mochida J, Shapiro IM, Risbud MV (2009) Activation of TonEBP by calcium controls {beta}1,3-glucuronosyltransferase-I expression, a key regulator of glycosaminoglycan synthesis in cells of the intervertebral disc. J Biol Chem **284**: 9824-9834.

Hiyama A, Gogate SS, Gajghate S, Mochida J, Shapiro IM, Risbud MV (2010a) BMP-2 and TGFbeta stimulate expression of beta1,3-glucuronosyl transferase 1 (GlcAT-1) in nucleus pulposus cells through AP1, TonEBP, and Sp1: role of MAPKs. J Bone Miner Res **25**: 1179-1190.

Hiyama A, Sakai D, Risbud MV, Tanaka M, Arai F, Abe K, Mochida J (2010b) Enhancement of intervertebral disc cell senescence by WNT/betacatenin signaling-induced matrix metalloproteinase expression. Arthritis Rheum **62**: 3036-3047.

Hiyama A, Sakai D, Tanaka M, Arai F, Nakajima D, Abe K, Mochida J (2011) The relationship between the Wnt/beta-catenin and TGF-beta/BMP signals in the intervertebral disc cell. J Cell Physiol **226**: 1139-1148.

Ho SN (2006) Intracellular water homeostasis and the mammalian cellular osmotic stress response. J Cell Physiol **206**: 9-15.

Hoffman H, Choi AW, Chang V, Kimball J, A SV, Virani R, Kim B, Niu T, Lu DC (2017) Aquaporin-1 expression in herniated human lumbar intervertebral discs. Global Spine J **7**: 133-140.

Hoffmann EK, Lambert IH, Pedersen SF (2009) Physiology of cell volume regulation in vertebrates. Physiol Rev **89**: 193-277.

Hooper L, Abdelhamid A, Ali A, Bunn DK, Jennings A, John WG, Kerry S, Lindner G, Pfortmueller CA, Sjostrand F, Walsh NP, Fairweather-Tait SJ, Potter JF,

Hunter PR, Shepstone L (2015) Diagnostic accuracy of calculated serum osmolarity to predict dehydration in older people: adding value to pathology laboratory reports. BMJ Open **5**: e008846.

Hu F, Zhu W, Wang L (2013) MicroRNA-203 up-regulates nitric oxide expression in temporomandibular joint chondrocytes *via* targeting TRPV4. Arch Oral Biol **58**: 192-199.

Hunter CJ, Bianchi S, Cheng P, Muldrew K (2007) Osmoregulatory function of large vacuoles found in notochordal cells of the intervertebral disc. Mol Cell Biomech 4: 227-237.

Ip WK, Medzhitov R (2015) Macrophages monitor tissue osmolarity and induce inflammatory response through NLRP3 and NLRC4 inflammasome activation. Nat Commun **6**: 6931.

Ishihara H, Warensjo K, Roberts S, Urban J (1997) Proteoglycan synthesis in the intervertebral disk nucleus: the role of extracellular osmolality. Am J Physiol **272**: C1499-C1506.

Jo AO, Ryskamp DA, Phuong TT, Verkman AS, Yarishkin O, MacAulay N, Krizaj D (2015) TRPV4 and AQP4 channels synergistically regulate cell volume and calcium homeostasis in retinal Muller glia. J Neurosci **35**: 13525-13537.

Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science **298**: 1911-1912.

Johnson ZI, Doolittle AC, Snuggs JW, Shapiro IM, Le Maitre CL, Risbud MV (2017) TNF-alpha promotes nuclear enrichment of the transcription factor TonEBP/NFAT5 to selectively control inflammatory but not osmoregulatory responses in nucleus pulposus cells. J Biol Chem **292**: 17561-17575.

Johnson ZI, Gogate SS, Day R, Binch A, Markova DZ, Chiverton N, Cole A, Conner M, Shapiro IM, Le Maitre CL, Risbud MV (2015) Aquaporin 1 and 5 expression decreases during human intervertebral disc degeneration: novel HIF-1-mediated regulation of aquaporins in NP cells. Oncotarget **6**: 11945-11958.

Johnson ZI, Shapiro IM, Risbud MV (2014) Extracellular osmolarity regulates matrix homeostasis in the intervertebral disc and articular cartilage: evolving role of TonEBP. Matrix Biol **40**: 10-16.

Jones RS, Morris ME (2016) Monocarboxylate transporters: therapeutic targets and prognostic factors in disease. Clin Pharmacol Ther **100**: 454-463.

Jung YK, Jang JA, Han MS, Kim G, Lee J, Han S (2017) Calcium-phosphate increases MMP3 and MMP13 through p38 map kinase and calcineurin signaling in hypertrophic chondrocyte. Osteoarthritis Cartilage **25**: S317.

Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, Kim HH (2006) Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents *in vivo* bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Free Radic Biol Med **40**: 1483-1493.

Kim JA, Sheen MR, Lee SD, Jung JY, Kwon HM (2009) Hypertonicity stimulates PGE2 signaling in the



renal medulla by promoting EP3 and EP4 receptor expression. Kidney Int **75**: 278-284.

Kim JS, Ellman MB, An HS, Yan D, van Wijnen AJ, Murphy G, Hoskin DW, Im HJ (2012) Lactoferricin mediates anabolic and anti-catabolic effects in the intervertebral disc. J Cell Physiol **227**: 1512-1520.

Kim NH, Hong BK, Choi SY, Moo Kwon H, Cho CS, Yi EC, Kim WU (2013) Reactive oxygen species regulate context-dependent inhibition of NFAT5 target genes. Exp Mol Med **45**: e32.

Kishi H, Nakagawa K, Matsumoto M, Suga M, Ando M, Taya Y, Yamaizumi M (2001) Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem **276**: 39115-39122.

Klawitter M, Quero L, Klasen J, Liebscher T, Nerlich A, Boos N, Wuertz K (2012) Triptolide exhibits anti-inflammatory, anti-catabolic as well as anabolic effects and suppresses TLR expression and MAPK activity in IL-1beta treated human intervertebral disc cells. Eur Spine J **21 Suppl 6**: S850-859.

Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F (2015) Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature **517**: 583-588.

Krupkova O, Zvick J, Wuertz-Kozak K (2017) The role of transient receptor potential channels in joint diseases. Eur Cell Mater **34**: 180-201.

Kulbacka J, Choromanska A, Rossowska J, Wezgowiec J, Saczko J, Rols MP (2017) Cell membrane rransport mechanisms: ion channels and electrical properties of cell membranes. Adv Anat Embryol Cell Biol **227**: 39-58.

Le Maitre CL, Freemont AJ, Hoyland JA (2004) Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol **204**: 47-54.

Lee JH, Kim M, Im YS, Choi W, Byeon SH, Lee HK (2008) NFAT5 induction and its role in hyperosmolar stressed human limbal epithelial cells. Invest Ophthalmol Vis Sci **49**: 1827-1835.

Lee JM, Song JY, Baek M, Jung HY, Kang H, Han IB, Kwon YD, Shin DE (2011a) Interleukin-1beta induces angiogenesis and innervation in human intervertebral disc degeneration. J Orthop Res **29**: 265-269.

Lee SD, Choi SY, Lim SW, Lamitina ST, Ho SN, Go WY, Kwon HM (2011b) TonEBP stimulates multiple cellular pathways for adaptation to hypertonic stress: organic osmolyte-dependent and -independent pathways. Am J Physiol Renal Physiol **300**: F707-715.

Li P, Gan Y, Wang H, Xu Y, Li S, Song L, Zhang C, Ou Y, Wang L, Zhou Q (2017) Role of the ERK1/2 pathway in osmolarity effects on nucleus pulposus cell apoptosis in a disc perfusion culture. J Orthop Res **35**: 86-92.

Li P, Gan Y, Xu Y, Li S, Song L, Li S, Li H, Zhou Q (2016) Osmolarity affects matrix synthesis in the nucleus pulposus associated with the involvement of

MAPK pathways: a study of *ex vivo* disc organ culture system. J Orthop Res **34**: 1092-1100.

Li X, Wu FR, Xu RS, Hu W, Jiang DL, Ji C, Chen FH, Yuan FL (2014a) Acid-sensing ion channel 1a-mediated calcium influx regulates apoptosis of endplate chondrocytes in intervertebral discs. Expert Opin Ther Targets **18**: 1-14.

Li Z, Yu X, Liang J, Wu WK, Yu J, Shen J (2014b) Leptin downregulates aggrecan through the p38-ADAMST pathway in human nucleus pulposus cells. PloS one **9**: e109595.

Liedtke W, Choe Y, Marti-Renom MA, Bell AM, Denis CS, Sali A, Hudspeth AJ, Friedman JM, Heller S (2000) Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell **103**: 525-535.

Liedtke W, Friedman JM (2003) Abnormal osmotic regulation in trpv4-/- mice. Proc Natl Acad Sci U S A **100**: 13698-13703.

Liu C, Montell C (2015) Forcing open TRP channels: mechanical gating as a unifying activation mechanism. Biochem Biophys Res Commun **460**: 22-25.

Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2000) Osmosis, water channels, and the regulation of cell volume. In: Molecular Cell Biology, 4th edition, WH Freeman and Company, New York, USA.

Lopez-Rodriguez C, Antos CL, Shelton JM, Richardson JA, Lin F, Novobrantseva TI, Bronson RT, Igarashi P, Rao A, Olson EN (2004) Loss of NFAT5 results in renal atrophy and lack of tonicityresponsive gene expression. Proc Natl Acad Sci U S A **101**: 2392-2397.

Lopez-Rodriguez C, Aramburu J, Jin L, Rakeman AS, Michino M, Rao A (2001) Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity **15**: 47-58.

Lorenz D, Krylov A, Hahm D, Hagen V, Rosenthal W, Pohl P, Maric K (2003) Cyclic AMP is sufficient for triggering the exocytic recruitment of aquaporin-2 in renal epithelial cells. EMBO Rep **4**: 88-93.

Luoma K, Riihimaki H, Luukkonen R, Raininko R, Viikari-Juntura E, Lamminen A (2000) Low back pain in relation to lumbar disc degeneration. Spine (Phila Pa 1976) **25**: 487-492.

Mah W, Sonkusare SK, Wang T, Azeddine B, Pupavac M, Carrot-Zhang J, Hong K, Majewski J, Harvey EJ, Russell L, Chalk C, Rosenblatt DS, Nelson MT, Seguin C (2016) Gain-of-function mutation in TRPV4 identified in patients with osteonecrosis of the femoral head. J Med Genet **53**: 705-709.

Maher C, Underwood M, Buchbinder R (2017) Non-specific low back pain. Lancet **389**: 736-747.

Makarov SS (2001) NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res **3**: 200-206.

Mavrogonatou E, Kletsas D (2009) High osmolality activates the G1 and G2 cell cycle checkpoints and



affects the DNA integrity of nucleus pulposus intervertebral disc cells triggering an enhanced DNA repair response. DNA Repair (Amst) **8**: 930-943.

Mavrogonatou E, Kletsas D (2010) Effect of varying osmotic conditions on the response of bovine nucleus pulposus cells to growth factors and the activation of the ERK and Akt pathways. J Orthop Res **28**: 1276-1282.

Mavrogonatou E, Kletsas D (2012) Differential response of nucleus pulposus intervertebral disc cells to high salt, sorbitol, and urea. J Cell Physiol **227**: 1179-1187.

McManus ML, Churchwell KB, Strange K (1995) Regulation of cell volume in health and disease. N Engl J Med **333**: 1260-1266.

McMillan D, Garbutt G, Adams M (1996) Effect of sustained loading on the water content of intervertebral discs: implications for disc metabolism. Ann Rheum Dis **55**: 880-887.

McNulty AL, Leddy HA, Liedtke W, Guilak F (2015) TRPV4 as a therapeutic target for joint diseases. Naunyn Schmiedebergs Arch Pharmacol **388**: 437-450.

Moeckel GW, Zhang L, Fogo AB, Hao CM, Pozzi A, Breyer MD (2003) COX2 activity promotes organic osmolyte accumulation and adaptation of renal medullary interstitial cells to hypertonic stress. J Biol Chem **278**: 19352-19357.

Molinos M, Almeida CR, Caldeira J, Cunha C, Goncalves RM, Barbosa MA (2015) Inflammation in intervertebral disc degeneration and regeneration. J R Soc Interface **12**: 20141191.

Muraki K, Iwata Y, Katanosaka Y, Ito T, Ohya S, Shigekawa M, Imaizumi Y (2003) TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res **93**: 829-838.

Nasto LA, Seo HY, Robinson AR, Tilstra JS, Clauson CL, Sowa GA, Ngo K, Dong Q, Pola E, Lee JY, Niedernhofer LJ, Kang JD, Robbins PD, Vo NV (2012) ISSLS prize winner: inhibition of NF-kappaB activity ameliorates age-associated disc degeneration in a mouse model of accelerated aging. Spine (Phila Pa 1976) **37**: 1819-1825.

Neidlinger-Wilke C, Mietsch A, Rinkler C, Wilke H-J, Ignatius A, Urban J (2012) Interactions of environmental conditions and mechanical loads have influence on matrix turnover by nucleus pulposus cells. J Orthop Res **30**: 112-121.

Neuhofer W, Holzapfel K, Fraek ML, Ouyang N, Lutz J, Beck FX (2004) Chronic COX-2 inhibition reduces medullary HSP70 expression and induces papillary apoptosis in dehydrated rats. Kidney Int **65**: 431-441.

Newell N, Little JP, Christou A, Adams MA, Adam CJ, Masouros SD (2017) Biomechanics of the human intervertebral disc: a review of testing techniques and results. J Mech Behav Biomed Mater **69**: 420-434.

Numata T, Kiyonaka S, Kato K, Takahashi N, Mori Y (2011) Activation of TRP channels in mammalian systems. In: TRP channels, Zhu MX edition, Boca Raton, FL, USA. Oegema TR Jr. (1993) Biochemistry of the intervertebral disc. Clin Sports Med **12**: 419-439.

Ohshima H, Urban JP (1992) The effect of lactate and pH on proteoglycan and protein synthesis rates in the intervertebral disc. Spine (Phila Pa 1976) **17**: 1079-1082.

Palacio-Mancheno PE, Evashwick-Rogler TW, Laudier DM, Purmessur D, Iatridis JC (2017) Hyperosmolarity induces notochordal cell differentiation with aquaporin3 upregulation and reduced N-cadherin expression. J Orthop Res **36**: 788-798.

Pan Z, Yang H, Mergler S, Liu H, Tachado SD, Zhang F, Kao WW, Koziel H, Pleyer U, Reinach PS (2008) Dependence of regulatory volume decrease on transient receptor potential vanilloid 4 (TRPV4) expression in human corneal epithelial cells. Cell Calcium **44**: 374-385.

Panahi G, Pasalar P, Zare M, Rizzuto R, Meshkani R (2018) High glucose induces inflammatory responses in HepG2 cells *via* the oxidative stress-mediated activation of NF-kappaB, and MAPK pathways in HepG2 cells. Arch Physiol Biochem **124**: 1-7.

Park JJ, Moon HJ, Park JH, Kwon TH, Park YK, Kim JH (2016) Induction of proinflammatory cytokine production in intervertebral disc cells by macrophage-like THP-1 cells requires mitogenactivated protein kinase activity. J Neurosurg Spine **24**: 167-175.

Perland E, Fredriksson R (2017) Classification systems of secondary active transporters. Trends Pharmacol Sci **38**: 305-315.

Phan MN, Leddy HA, Votta BJ, Kumar S, Levy DS, Lipshutz DB, Lee SH, Liedtke W, Guilak F (2009) Functional characterization of TRPV4 as an osmotically sensitive ion channel in porcine articular chondrocytes. Arthritis Rheum **60**: 3028-3037.

Pritchard S, Erickson GR, Guilak F (2002) Hyperosmotically induced volume change and calcium signaling in intervertebral disk cells: the role of the actin cytoskeleton. Biophys J **83**: 2502-2510.

Qu YJ, Zhang X, Fan ZZ, Huai J, Teng YB, Zhang Y, Yue SW (2016) Effect of TRPV4-p38 MAPK pathway on neuropathic pain in rats with chronic compression of the dorsal root ganglion. Biomed Res Int **2016**: 6978923.

Rabbani G, Choi I (2018) Roles of osmolytes in protein folding and aggregation in cells and their biotechnological applications. Int J Biol Macromol **109**: 483-491.

Racz B, Reglodi D, Fodor B, Gasz B, Lubics A, Gallyas F, Jr., Roth E, Borsiczky B (2007) Hyperosmotic stress-induced apoptotic signaling pathways in chondrocytes. Bone **40**: 1536-1543.

Rajamaki K, Mayranpaa MI, Risco A, Tuimala J, Nurmi K, Cuenda A, Eklund KK, Oorni K, Kovanen PT (2016) p38delta MAPK: a novel regulator of NLRP3 inflammasome activation with increased expression in coronary atherogenesis. Arterioscler Thromb Vasc Biol **36**: 1937-1946.



Ren Y, Lu H, Reinach PS, Zheng Q, Li J, Tan Q, Zhu H, Chen W (2017) Hyperosmolarity-induced AQP5 upregulation promotes inflammation and cell death *via* JNK1/2 Activation in human corneal epithelial cells. Sci Rep **7**: 4727.

Reuss L (2012) Water transport across cell membranes. Wiley Online Library.

Richardson SM, Knowles R, Marples D, Hoyland JA, Mobasheri A (2008) Aquaporin expression in the human intervertebral disc. J Mol Histol **39**: 303-309.

Risbud MV, Shapiro IM (2014) Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol **10**: 44-56.

Roth I, Leroy V, Kwon HM, Martin PY, Feraille E, Hasler U (2010) Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-kappaB activity. Mol Biol Cell **21**: 3459-3474.

Rottmar M, Mhanna R, Guimond-Lischer S, Vogel V, Zenobi-Wong M, Maniura-Weber K (2014) Interference with the contractile machinery of the fibroblastic chondrocyte cytoskeleton induces re-expression of the cartilage phenotype through involvement of PI3K, PKC and MAPKs. Exp Cell Res **320**: 175-187.

Roughley PJ, Alini M, Antoniou J (2002) The role of proteoglycans in aging, degeneration and repair of the intervertebral disc. Biochem Soc Trans **30**: 869-874.

Sadowska A, Touli E, Hitzl W, Greutert H, Ferguson SJ, Wuertz-Kozak K, Hausmann ON (2017) Inflammaging in cervical and lumbar degenerated intervertebral discs: analysis of proinflammatory cytokine and TRP channel expression. Eur Spine J **27**: 564-577.

Sano M, Fukuda K, Sato T, Kawaguchi H, Suematsu M, Matsuda S, Koyasu S, Matsui H, Yamauchi-Takihara K, Harada M, Saito Y, Ogawa S (2001) ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen speciesmediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res **89**: 661-669.

Schwartz L, Guais A, Pooya M, Abolhassani M (2009) Is inflammation a consequence of extracellular hyperosmolarity? J Inflamm (Lond) **6**: 21.

Sheikh-Hamad D, Gustin MC (2004) MAP kinases and the adaptive response to hypertonicity: functional preservation from yeast to mammals. Am J Physiol Renal Physiol **287**: F1102-1110.

Shirazi-Adl A (2006) Analysis of large compression loads on lumbar spine in flexion and in torsion using a novel wrapping element. J Biomech **39**: 267-275.

Sivan S, Neidlinger-Wilke C, Würtz K, Maroudas A, Urban JP (2006) Diurnal fluid expression and activity of intervertebral disc cells. Biorheology **43**: 283-291.

Sivan SS, Wachtel E, Roughley P (2014) Structure, function, aging and turnover of aggrecan in the intervertebral disc. Biochim Biophys Acta **1840**: 3181-3189.

Snuggs J, Day R, Chiverton N, Cole A, Bunning R, Conner M, Le Maitre CL (2017) Aquaporin expression

in the human intervertebral disc. Orthopaedic Proceedings **99-B SUPP 10**: 23.

Song Y, Wang Y, Zhang Y, Geng W, Liu W, Gao Y, Li S, Wang K, Wu X, Kang L, Yang C (2017) Advanced glycation end products regulate anabolic and catabolic activities *via* NLRP3-inflammasome activation in human nucleus pulposus cells. J Cell Mol Med **21**: 1373-1387.

Studer RK, Aboka AM, Gilbertson LG, Georgescu H, Sowa G, Vo N, Kang JD (2007) p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Spine (Phila Pa 1976) **32**: 2827-2833.

Sun Z, Yin Z, Liu C, Liang H, Jiang M, Tian J (2015) IL-1beta promotes ADAMTS enzyme-mediated aggrecan degradation through NF-kappaB in human intervertebral disc. J Orthop Surg Res **10**: 159.

Sztrolovics R, Alini M, Roughley PJ, Mort JS (1997) Aggrecan degradation in human intervertebral disc and articular cartilage. Biochem J **326**: 235-241.

Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest **107**: 7-11.

Takada T, Nishida K, Doita M, Kurosaka M (2002) Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine (Phila Pa 1976) **27**: 1526-1530.

Takeuchi K, Hayashi S, Matumoto T, Hashimoto S, Takayama K, Chinzei N, Kihara S, Haneda M, Kirizuki S, Kuroda Y, Tsubosaka M, Nishida K, Kuroda R (2018) Downregulation of aquaporin 9 decreases catabolic factor expression through nuclear factor-κB signaling ins chondrocytes. Int J Mol Med **42**: 1548-1558.

Tang P, Gu JM, Xie ZA, Gu Y, Jie ZW, Huang KM, Wang JY, Fan SW, Jiang XS, Hu ZJ (2018) Honokiol alleviates the degeneration of intervertebral disc *via* suppressing the activation of TXNIP-NLRP3 inflammasome signal pathway. Free Radic Biol Med **120**: 368-379.

Tas U, Cayli S, Inanir A, Ozyurt B, Ocakli S, Karaca ZI, Sarsilmaz M (2012) Aquaporin-1 and aquaporin-3 expressions in the intervertebral disc of rats with aging. Balkan Med J **29**: 349-353.

Trama J, Go WY, Ho SN (2002) The osmoprotective function of the NFAT5 transcription factor in T cell development and activation. J Immunol **169**: 5477-5488.

Tsai TT, Danielson KG, Guttapalli A, Oguz E, Albert TJ, Shapiro IM, Risbud MV (2006) TonEBP/ OREBP is a regulator of nucleus pulposus cell function and survival in the intervertebral disc. J Biol Chem **281**: 25416-25424.

Tsai TT, Guttapalli A, Agrawal A, Albert TJ, Shapiro IM, Risbud MV (2007) MEK/ERK signaling controls osmoregulation of nucleus pulposus cells of the intervertebral disc by transactivation of TonEBP/ OREBP. J Bone Miner Res **22**: 965-974.

Tsirimonaki E, Fedonidis C, Pneumaticos SG, Tragas AA, Michalopoulos I, Mangoura D (2013) PKCepsilon signalling activates ERK1/2, and



regulates aggrecan, ADAMTS5, and miR377 gene expression in human nucleus pulposus cells. PloS One 8: e82045.

Uchiyama Y, Cheng CC, Danielson KG, Mochida J, Albert TJ, Shapiro IM, Risbud MV (2007) Expression of acid-sensing ion channel 3 (ASIC3) in nucleus pulposus cells of the intervertebral disc is regulated by p75NTR and ERK signaling. J Bone Miner Res **22**: 1996-2006.

Uchiyama Y, Guttapalli A, Gajghate S, Mochida J, Shapiro IM, Risbud MV (2008) SMAD3 functions as a transcriptional repressor of acid-sensing ion channel 3 (ASIC3) in nucleus pulposus cells of the intervertebral disc. J Bone Miner Res **23**: 1619-1628.

Ueda T, Shikano M, Kamiya T, Joh T, Ugawa S (2011) The TRPV4 channel is a novel regulator of intracellular Ca2+ in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol **301**: G138-147.

Urban JPG (1993) The effect of physical factors on disk cell metabolism. In: Musculoskeletal softtissue aging: impact on mobility. Buckwalter JA, Goldberg VM, Woo SLY edition. American Academy of Orthopaedic Surgeons, Rosemont, IL, USA: 391-412.

Urban JP, Maroudas A (1981) Swelling of the intervertebral disc *in vitro*. Connect Tissue Res **9**: 1-10.

Urban JP, Maroudas A, Bayliss MT, Dillon J (1979) Swelling pressures of proteoglycans at the concentrations found in cartilaginous tissues. Biorheology **16**: 447-464.

Urban JP, McMullin JF (1988) Swelling pressure of the lumbar intervertebral discs: influence of age, spinal level, composition, and degeneration. Spine (Phila Pa 1976) **13**: 179-187.

Urban JP, Roberts S (2003) Degeneration of the intervertebral disc. Arthritis Res Ther **5**: 120-130.

van Dijk B, Potier E, Ito K (2011) Culturing bovine nucleus pulposus explants by balancing medium osmolarity. Tissue Eng Part C Methods **17**: 1089-1096.

van Dijk B, Potier E, van DM, Langelaan M, Papen-Botterhuis N, Ito K (2015) Reduced tonicity stimulates an inflammatory response in nucleus pulposus tissue that can be limited by a COX-2-specific inhibitor. J Orthop Res **33**: 1724-1731.

Vriens J, Watanabe H, Janssens A, Droogmans G, Voets T, Nilius B (2004) Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4. Proc Natl Acad Sci U S A **101**: 396-401.

Walker BF (2000) The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord **13**: 205-217.

Walter BA, Purmessur D, Moon A, Occhiogrosso J, Laudier DM, Hecht AC, Iatridis JC (2016) Reduced tissue osmolarity increases TRPV4 expression and pro-inflammatory cytokines in intervertebral disc cells. Eur Cell Mater **32**: 123-136.

Wang F, Zhu Y (2011) Aquaporin-1: a potential membrane channel for facilitating the adaptability

of rabbit nucleus pulposus cells to an extracellular matrix environment. J Orthop Sci **16**: 304-312.

Wang M, Tang D, Shu B, Wang B, Jin H, Hao S, Dresser KA, Shen J, Im HJ, Sampson ER, Rubery PT, Zuscik MJ, Schwarz EM, O'Keefe RJ, Wang Y, Chen D (2012) Conditional activation of beta-catenin signaling in mice leads to severe defects in intervertebral disc tissue. Arthritis Rheum **64**: 2611-2623.

Weinstein MM, Tompson SW, Chen Y, Lee B, Cohn DH (2014) Mice expressing mutant Trpv4 recapitulate the human TRPV4 disorders. J Bone Miner Res **29**: 1815-1822.

Wieser S, Horisberger B, Schmidhauser S, Eisenring C, Brugger U, Ruckstuhl A, Dietrich J, Mannion AF, Elfering A, Tamcan O, Muller U (2011) Cost of low back pain in Switzerland in 2005. Eur J Health Econ **12**: 455-467.

Williams GR (2013) Thyroid hormone actions in cartilage and bone. Eur Thyroid J **2**: 3-13.

Wong W (2009) Focus issue: coping with cellular stress. Sci Signal **2**: eg14. DOI: 10.1126/ scisignal.296eg14.

Wuertz K, Godburn K, Iatridis JC (2009) MSC response to pH levels found in degenerating intervertebral discs. Biochem Biophys Res Commun **379**: 824-829.

Wuertz K, Urban JP, Klasen J, Ignatius A, Wilke HJ, Claes L, Neidlinger-Wilke C (2007) Influence of extracellular osmolarity and mechanical stimulation on gene expression of intervertebral disc cells. J Orthop Res **25**: 1513-1522.

Xie H, Jing Y, Xia J, Wang X, You C, Yan J (2016) Aquaporin 3 protects against lumbar intervertebral disc degeneration *via* the Wnt/beta-catenin pathway. Int J Mol Med **37**: 859-864.

Xu F, Satoh E, Iijima T (2003) Protein kinase C-mediated Ca2+ entry in HEK 293 cells transiently expressing human TRPV4. Br J Pharmacol **140**: 413-421.

Xu K, Chen W, Wang X, Peng Y, Liang A, Huang D, Li C, Ye W (2015) Autophagy attenuates the catabolic effect during inflammatory conditions in nucleus pulposus cells, as sustained by NF-kappaB and JNK inhibition. Int J Mol Med **36**: 661-668.

Yang C, Cao P, Gao Y, Wu M, Lin Y, Tian Y, Yuan W (2016) Differential expression of p38 MAPK alpha, beta, gamma, delta isoforms in nucleus pulposus modulates macrophage polarization in intervertebral disc degeneration. Sci Rep 6: 22182.

Yang XR, Lin AH, Hughes JM, Flavahan NA, Cao YN, Liedtke W, Sham JS (2012) Upregulation of osmomechanosensitive TRPV4 channel facilitates chronic hypoxia-induced myogenic tone and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol **302**: L555-568.

Yoder N, Yoshioka C, Gouaux E (2018) Gating mechanisms of acid-sensing ion channels. Nature **555**: 397-401.

Yuan FL, Zhao MD, Jiang DL, Jin C, Liu HF, Xu MH, Hu W, Li X (2016) Involvement of acid-sensing



ion channel 1a in matrix metabolism of endplate chondrocytes under extracellular acidic conditions through NF-kappaB transcriptional activity. Cell Stress Chaperones **21**: 97-104.

Zair ZM, Eloranta JJ, Stieger B, Kullak-Ublick GA (2008) Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics **9**: 597-624.

Zhang W, Zitron E, Homme M, Kihm L, Morath C, Scherer D, Hegge S, Thomas D, Schmitt CP, Zeier M, Katus H, Karle C, Schwenger V (2007) Aquaporin-1 channel function is positively regulated by protein kinase C. J Biol Chem **282**: 20933-20940.

Zhongyi S, Sai Z, Chao L, Jiwei T (2015) Effects of nuclear factor kappa B signaling pathway in human intervertebral disc degeneration. Spine (Phila Pa 1976) **40**: 224-232.

Discussion with Reviewers

Jivko Stoyanov: A change of disc osmolarity from the normal high value of 450 mOsm/L to a 'mean' of ~ 300 mOsm/L is a consequence of a cascade of degenerative changes which lead to the decrease in extracellular proteoglycan content and waterretaining capacity of the disc. How would a therapy related to osmolarity regulation or osmosensing target such a specific mechanism which is at the root of the problem?

Authors: Indeed, targeting osmoregulation or osmosensing in IVD cells would not recuperate the degenerative changes occurring in the IVD and the consequent drop of osmolarity. These approaches are rather intended to let IVD cells cope better with the arising hypo-osmotic microenvironment, thus preventing/minimising induction of detrimental cellular responses that can further accelerate the degenerative cascade.

Junxuan Ma: NP cells are naturally living in a harsh microenvironment with a high osmolarity, which is different from other tissues. How is the response to osmolarity different between NP and other cells?

Authors: NP cells are stiffer and more viscous in comparison to AF cells and many other cell types due to differences in the cytoskeletal arrangement, consequently leading to different responses to an altered osmotic environment (Pritchard *et al.*, 2002).

Junxuan Ma: A decrease in cell volume due to the hyper-osmotic stress is mentioned by the authors. What is the subsequent cellular response, *e.g.* which pathways are activated by the cell volume changes, leading to apoptosis or inflammation?

Authors: Hyper-osmotic stress (*i.e.* increase in the extracellular osmolality) leads to cell shrinkage as water moves out of the cell, generating Ca²⁺ transients (Pritchard *et al.*, 2002) and subsequent activation of MAPKs (p38, ERK and JNK) (Dong *et al.*, 2014). These

Ca²⁺ transients, together with the MAPKs, activate TonEBP/NFAT5, which plays a key role in IVD cell osmoadaptation. In addition, TonEBP/NFAT5 can also induce inflammation, e.g. through its crosstalk with the NF-κB pathway (Johnson *et al.*, 2017). As such, activation of the same signal transduction pathway can lead to distinctive responses, depending on the cellular microenvironment. Also, hyper-osmoticallyactivated p38/MAPK can lead to DNA damage and trigger apoptosis by activating G2 and G1 cell cycle check points (Dong et al., 2014; Mavrogonatou and Kletsas, 2009). Conflicting results are reported concerning hyper-osmotic stress and activation of the ERK pathway (see manuscript), but these differences may be due to heterogeneous experimental set-ups, such as culture conditions or animal model used.

Junxuan Ma: Inflammation causes further damage to the tissue, but also triggers repair. For the treatment, the authors mentioned the inhibition of inflammation while leaving osmoadaptive mechanism to function. Yet, what if there is a positive aspect of the inflammation being present?

Authors: Indeed, inflammation can have positive effects, for example during tissue injury or infection. However, in other instances, inflammation can also be viewed as a malfunction of a tissue and, as such, can be tissue-/cell-/ECM-induced (*e.g.* through signals released by stressed IVD cells). In the context of this review, the word inflammation is used with the meaning of 'chronic pro-inflammatory response', which is characterised by prolonged, increased expression/presence of pro-inflammatory mediators (*e.g.* TNF- α , IL-1 β , IL-8) and catabolic enzymes (*e.g.* MMPs) and, at the same time, reduced expression/ presence of inflammation antagonists (*e.g.* IL1RA, TNFRA).

Reviewer: Please provide more details of how CRISPR in osmosensing molecules may be used in IVD degeneration.

Authors: Gene editing techniques (e.g. CRISPR) can be used to modulate the expression/activity of osmosensing-associated genes in locally-delivered autologous therapeutic cells (Krupkova et al., 2018, additional reference). To date, CRISPR is used to generate inflammation-resistant chondrocytes and IVD cells. As an example, stable CRISPR/Cas9 knockout of the surface receptor IL1R1 results in inflammation-resistant cell population with superior properties over non-edited therapeutic cells (Karlsen et al., 2016, additional reference). Moreover, two surface receptors (TNFR1, IL1R1) are successfully targeted by epigenome editing in human primary IVD cells, suggesting the feasibility of this approach (N.L. Farhang, 2018, additional reference). Therefore, osmosensing receptors (such as TRPV4) and genes regulating their activity, synthesis and transport of osmolytes can be potentially targeted by CRISPR. CRISPR-based methods include dCas fused to VP64 domains for gene activation (Perez-Pinera et al., 2013,



additional reference), dCas fused with KRAB for gene silencing (Gilbert *et al.*, 2013, additional reference) or Cas-mediated DNA cuts for gene knock-out (Jinek *et al.*, 2013, additional reference).

Additional references

Farhang N, Lawrence B, Bowles RD (2018) Lentiviral CRISPR epigenome editing: a potential gene therapy strategy for disc degeneration. In: Proceedings of the transactions of the annual meeting of the Orthopaedic Research Society, New Orleans, LA, USA.

Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell **154**: 442-451. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J (2013) RNA-programmed genome editing in human cells. Elife **2**: e00471.

Karlsen T, Pernas P, Staerk J, Caglayan S, Brinchmann J (2016) Generation of IL1β-resistant chondrocytes using CRISPR-CAS genome editing. Osteoarthritis Cartilage **24**: S325.

Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K (2018) The potential of CRISPR/ Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine **1**: e1003.

Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods **10**: 973-976

Editor's note: The Scientific Editor responsible for this paper was Mauro Alini.

